



nrgene

Corporate Presentation

January 2021

DISCLAIMER

The objective of this presentation is to present the activity of **Energim.R Technologies 2009 LTD** and its subsidiaries (collectively, the “**Company**”) and to provide preliminary and basic information regarding its activities. In accessing this presentation, you agree to be bound by the following terms and conditions.

This presentation does not constitute and should not be interpreted as an offer or an invitation to purchase and/or an issuance of securities of the Company. This presentation is intended for informational purposes only. This presentation does not constitute an offer of the Company's securities to the public. Such an offer, if and to extent it will be made, will be made through a prospectus which the Company will publish subject to the approval of the Israel Securities Authority and the Tel Aviv Stock Exchange (the “**Prospectus**”).

The information included in this presentation is a summary only and does not exhaust or include all of the information regarding the Company and its business, nor is it a substitute for careful inspection of the Prospectus and the Company's financial reports, which will be attached to the Prospectus and/or the need for professional advice before purchasing the Company's securities on the basis of the Prospectus.

The information presented in this presentation does not constitute a recommendation or an opinion nor is it a substitute for the collection and analysis of independent and additional information of any potential investor. Every potential investor should take independent advice and guidance in connection with its potential investment, including tax advice that takes into account its tax status.

The data presented in this presentation is based on the Company's financial statements as of June 30, 2020, unless otherwise stated.

This presentation shall not be relied upon and shall not be construed as any representation or obligation, including with regard to the completeness or accuracy of the information included herein. The Company, its employees, its officers and its shareholders will not be liable for damages and/or losses that may be caused as a result of the use of the information presented in this presentation. The Company is not responsible for any future change in the economic, financial or legal situation concerning the Company and its business. This presentation includes information that is based on external sources and studies, which have not been independently reviewed by the Company. This information shall not be considered an opinion, rather it is general and non-binding information.

This presentation includes forecasts, estimates, assessments and other information pertaining to future events and/or matters, whose materialization is uncertain and is beyond the Company's control, and which constitute forward-looking information, as defined in the Securities Law, 5728-1968. More specifically, the presentation includes information regarding an estimated growth in the Company's revenues in the next two years, pursuant estimations of the Company's management, based on assumptions regarding the Company's growth rate, completion of negotiations and execution of binding agreements, state of markets and the demand for the Company's products. Such information may not materialize, in whole or in part, or may materialize in a manner significantly different from such forecast. Forward-looking information is based solely on the Company's subjective assessment, based on facts and data regarding the current condition of the Company's business and macroeconomic facts and figures, all as known to the Company at the time of preparation of this presentation. The materialization or non-materialization of the forward-looking information will be affected, inter alia, by risk factors characteristic of the Company's activity, as well as by developments in the general environment, in market conditions and in external factors affecting the Company's activity, and other such events which cannot be estimated in advance and which are beyond the Company's control. The Company does not undertake to update and/or change any such forecast and/or assessment to reflect events and/or circumstances postdating this presentation.

About NRGene

The world leading genomics AI company for seed breeding



NRGene is a software company using artificial intelligence to analyze genomic big data in order to optimize and accelerate natural (non-GMO) breeding of plants and animals used in agriculture.



NRGene's technology is widely used to create disease resistant and climate resilient varieties, with healthier nutritional components and higher yields.



The company's solutions have been broadly implemented across 250 projects. Leading companies are using NRGene's AI tools to improve agriculture produce in a variety of industries: food & beverage, rubber, paper & pulp and others.



Cumulative projected revenue growth of between 150%-250% by 2022



Leading customers using NRGene's technology



\$6.4B

* Market Size
(2025 forecast)

2015

Commercial
Launch

\$9M

Backlog

\$8M

Sales in
2019

> 100

Customers

30

Countries

* 20% of the Global Bioinformatics Market

Examples of Potential Projects Using NRGene's Technology

Breeding non
allergenic peanuts



Breeding for taste
and texture of
legumes, fit for the
alternative proteins
market



Breeding of non
allergenic wheat
(Suitable for high
quality bread
production)



Breeding oranges
resistant to a
destructive virus



Breeding
strawberries
with longer shelf life



Breeding aftertaste
free stevia
sweetener



NRGene's Leadership:

A team with vast experience in the development and global commercialization of AI for agriculture



Gil Ronen, PhD
CEO &
Co-Founder



Ehud Belder
CFO



Asaf Levi
Chairman of the
Board



Noam Barkai
VP R&D



Guy Kol
VP Strategic Accounts
& Co-Founder



Lydia Willing
Corporate Sales
Director



Kobi Baruch, PhD
VP GAS (Genomic
Analysis Services)



Employees and Advisors

The company has 50 employees worldwide, including PhDs (35%) and graduates from elite IDF cyber units, as well as world-leading advisors



Vincent Petiard, PhD
Ex Nestle



Prof. Assaf Distelfeld
Director, Institute of
Evolution
University of Haifa



Roy Cantrell, PhD
Ex Monsanto



Paul Chomet, PhD
Ex Monsanto



The Need

Rapid variety development and improvement to meet the increasing global food demand, climate changes and the spread of diseases and pests



10 billion USD are invested worldwide annually in breeding new agriculture varieties



Today, breeding of new varieties takes 5-15 years. These long breeding cycles fail to meet the growing and changing demand for agricultural produce




Huge volumes of data are produced in order to accelerate breeding processes. Yet, **less than 1% of relevant data is utilized** due to the lack of efficient software tools.




Value Chain and Target Market

Accelerate crop/variety development to meet market demand



NRGene's Solution

AI tools that analyze full genomics data and identify the optimal genetic makeup for any need, while creating a roadmap for efficient integration into new varieties



- ✓ Reducing $\approx 50\%$ in new seed development time
- ✓ Reducing $\approx 50\%$ of R&D costs

NRGene's Solution

NRGene's technology optimizes varieties development and reduces their time to market, thus leading to an increase in their market potential

TRADITIONAL

Long cycle | Expensive | Low success rate



NRGENE's AI SOLUTION

Faster | Reduced costs | High success rate



The company estimates, that more productive disease resistant bread wheat varieties are expected to reach the market 5 years earlier and increase farmers' income while reducing the use of chemicals.

NRGene's Advantages

Value Proposition for Improving Variety Development



Shorter and more efficient R&D



Lower R&D Cost



Broader data usage in decision making process



Cost efficient genomics big data management relying on cloud technologies (AWS)



Outsourcing genomics analytics to a reliable and efficient partner



NRGene is an Advanced Technology Partner of **Amazon Web Services (AWS)**



Amazon Web Services (AWS) managed database services enables dynamic scalability, faster processing, easier visualizations, higher availability and resiliency, and stronger security.



Assembling the Wheat Genome has Led to Worldwide Recognition of NRGene's Technological Superiority

- Wheat is the source for bread, pasta and 20% of all food consumed by mankind.
- Assembling the full wheat genome is essential for efficient breeding of wheat.
- The once 'holy grail' of all crops, the 16Gbp hexaploid wheat genome (5 times larger than the human genome) was challenged by a global consortium of 1,700 scientists who failed to complete the full assembly after 10 years of hard work.
- NRGene stepped in using its AI technology and successfully assembled the **full** genome of the hexaploidy wheat in just 10 days.
- The genome assembly was featured on the cover of Science Magazine.

“The quality is breathtaking...NRGene's results are just amazing and will have a major impact”

Prof. Nils Stein, Germany's Leibniz Institute of Plant Genetics and Crop Plant Research (IPK)

Collaboration Agreement

02/2018

BRIDGESTONE COLLABORATING WITH NRGENE ON GUAYULE RESEARCH

Bridgestone signed an agreement to enhance its U.S. alternative domestic natural rubber breeding program

“We are looking forward to utilizing NRGene’s capabilities and experience in agricultural genome analytics to move our guayule breeding program to a new level.”



Nizar Trigui

Chief Technology officer Bridgestone Americas



The largest tire and rubber company.



Successful Market Penetration in over 30 Countries

International activity in various territories with specific characteristics and requirements



The company's unique and efficient solutions have been validated across 250 projects worldwide in all key crops.

These achievements led to NRGene's global expansion, turning its solutions into an integral part of the modern breeding process



Customers and Strategic Partners

Among NRGene's customers are many Fortune 500 companies

In a relatively short period, NRGene collaborated with some of the leading companies in the industry, who have implemented NRGene's AI solutions into their breeding programs.

Seeds and Agro-chemicals



Natural Raw Material



Food & Beverages



Cannabis & Hemp



Target Industries

The company estimates that the global plant genomics market is rapidly growing and predicted to reach US\$12B in 2025

NRGene focuses on expanding its business in 4 industries, where its technological value has been validated



Seeds and Agro-chemicals
> 1000 companies

Seed companies investing in research and innovation of new varieties breeding



Food & Beverages
> 500 companies

Leading food & beverages companies striving to improve processing and quality of their agriculture-based products



Natural Raw Material
> 500 companies

Paper & pulp, automotive, rubber and packaging companies that rely on agricultural raw materials and are looking to ensure their high quality and stable alternative supply source




Cannabis & Hemp
> 200 companies

Leading producers looking to develop new and stable varieties for the use of the Cannabis plant in pharma, cosmetics, dietary supplements etc.

Key Crops

The company has exclusive expertise in all key crops



Business Model

The company provides AI-based software solutions through two complementary business models

1

Multi-year Project / Subscription

The customer engages in a multi-year agreement and receives a cloud-access to the company's software and analytics to support their breeding programs.

2


Joint IP Development

The company joins forces with its clients to conduct co-development of new elite varieties (IP). The revenue includes cost reimbursement plus royalties from sales of the co-developed products.



New Market Expansion: Genotyping

Market size of genotyping for agricultural uses reached \$1.4B in 2018 with CARG of 17% between 2019-2023



30%-70% cost reduction of genotyping tests

More complete and accurate DNA database

Above 1000 potential clients

Number of signed contracts with global customers, since product launch in September 2020

New Market Expansion: Royalty based product development

The company expects initial revenues from royalty-based projects no later than the end of 2021



Maize, chili and rice breeding for the Indian market

Disease resistant tomato breeding

Oil crop breeding for fungus disease resistance

Herbs breeding program

Legume and other crops breeding for alternative protein industry

Oil and protein crop breeding for adaptation for cold climates

In development

In planning

Royalty based product

Seeds sales

Trait commercialization and seeds sales

Trait commercialization and seeds sales

Seeds sales

Seeds and protein powder sales

Seeds sales



Business Status

NRGene's successful penetration into the market coupled with its proven value to major customers, positions the company at a breakthrough moment



Successful Market Penetration: NRGene successfully signed deals with worldwide market-leaders



Building market awareness: Unique services with proven capabilities to deliver value in various industries




Proven business model: Has the potential for significant short- and long-term revenue



Market expansion: Ready to scale-up AI systems after completing more than 250 projects focused on product improvement.



Knowledge, experience and expertise: The company has curated a robust knowledge base, [based on data accumulation] including exclusive expertise in all key crops.





Case Study: Collaboration Evolvement

Agreement with the world leading plant breeding company, Bayer (Acquired Monsanto for \$66B on 2018)



01/2017
Multi Year Agreement

Monsanto has signed a multi year agreement for the use of GenoMAGIC™ platform for genomic analysis

“ Our focus on data is allowing us make better decisions than ever before – and with GenoMAGIC, we expect to provide our plant breeders with a more comprehensive view to improve their analyses and decisions. ”



Dr. Tom Osborn,
Molecular breeding technology director for Monsanto

MONSANTO AND NRGENE ANNOUNCE GLOBAL LICENSING AGREEMENT FOR BIG DATA GENOMIC ANALYSIS TECHNOLOGY



10/2017
Successful implementation in the first crop

Successful implementation of NRGene’s technology – GenoMAGIC™ in the Monsanto breeding program

“ We have been impressed with NRGene’s integrated analytics platform so far, and look forward to evaluating its impact on our molecular breeding program. ”



Dr. Tom Osborn,
Molecular breeding technology director for Monsanto

NRGENE’S GENOMIC ANALYSIS PROJECT WITH MONSANTO ADVANCES



12/2018
Implementation of the technology in a few additional crops

Expanded licensing agreement for use of GenoMAGIC™ with several additional crops

“ We were most satisfied by the ability of NRGene’s integrated analytics platform to support our genomics-based, molecular breeding pipeline. We are excited to broaden the use of GenoMAGIC to more of our key crops. ”



Dr. Ruth Wagner,
Genome & Marker design lead for Bayer’s Crop Science Division






NRGENE ANNOUNCES EXPANDED LICENSING AGREEMENT WITH BAYER FOR THE GENOMAGIC PLATFORM

* In June 2018, Bayer completed the acquisition of Monsanto

Strategy

Expanding new and existing customer base and utilizing the company's software in a 5x5x5 model.

Growth in 5 years of x5 customers, x5 in average deal size, by:

-  Geographic expansion to broaden the usage of the software in additional projects
-  Organic development of complementary products (SNPer, CRISPER-AI)
-  Acquisition of companies / complementary products
-  Establishment and commercialization of unique proprietary databases for every key crop
-  Building collaborations with leading customers based on royalties on usage of the company's AI tools and databases



Summary



More than a decade of accumulated knowledge and experience granting the company a distinct competitive advantage in the AI space



Validated business model and proof of concept for successful collaborations, based on royalties from sales of seeds and end products



Cumulative projected revenue growth of between 150%-250% by 2022



Cutting-edge technology, validated by major customers in the field



Opportunity for significant growth within new and existing customers



Capital raised will support accelerated global expansion





nrgene

THANK YOU